FDA grants Priority Review to GW's Epidiolex for seizures

On Thursday, GW Pharmaceuticals plc (NASDAQ:GWPH) said FDA accepted and granted Priority Review to an NDA for Epidiolex cannabidiol as an adjunctive treatment for seizures associated with Dravet syndrome and Lennox-Gastaut syndrome. Its PDUFA date is June 27, 2018.

GW expects an FDA advisory committee to discuss the NDA. ...